{"id":"halobetasol","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL1200908","moleculeType":"Small molecule","molecularWeight":"484.97"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"4cb1f7b3-c412-6fc7-e063-6394a90a63c9","title":"HALOBETASOL PROPIONATE LOTION [CORAL WAY PHARMA, LLC]"},"ecosystem":[],"_scrapedAt":"2026-03-28T02:40:36.413Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05608499","phase":"PHASE3","title":"Duobrii Treatment of Acne Keloidalis Nuchae (AKN)","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-10-26","conditions":"Acne Keloidalis Nuchae, AKN","enrollment":15},{"nctId":"NCT05203315","phase":"PHASE3","title":"Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults","status":"COMPLETED","sponsor":"Austin Institute for Clinical Research","startDate":"2022-01-13","conditions":"Plaque Psoriasis","enrollment":21},{"nctId":"NCT05872256","phase":"PHASE4","title":"A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2023-06-01","conditions":"Scalp Psoriasis","enrollment":20},{"nctId":"NCT06042647","phase":"PHASE4","title":"Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2023-07-13","conditions":"Psoriasis Vulgaris","enrollment":10},{"nctId":"NCT04720105","phase":"PHASE4","title":"Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2020-11-19","conditions":"Palmoplantar Psoriasis, Plaque Psoriasis","enrollment":22},{"nctId":"NCT05348200","phase":"PHASE2","title":"Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids","status":"COMPLETED","sponsor":"Citius Pharmaceuticals, Inc.","startDate":"2022-04-22","conditions":"Hemorrhoids","enrollment":304},{"nctId":"NCT06015152","phase":"NA","title":"Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2022-08-01","conditions":"Scalp Psoriasis","enrollment":90},{"nctId":"NCT03992261","phase":"PHASE4","title":"Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis","status":"COMPLETED","sponsor":"Mayne Pharma International Pty Ltd","startDate":"2019-06-14","conditions":"Plaque Psoriasis","enrollment":24},{"nctId":"NCT05282771","phase":"EARLY_PHASE1","title":"A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2021-04-16","conditions":"Plaque Psoriasis","enrollment":402},{"nctId":"NCT03212963","phase":"PHASE4","title":"Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%","status":"TERMINATED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2017-03-21","conditions":"Plaque Psoriasis","enrollment":16},{"nctId":"NCT00803166","phase":"","title":"Randomized Study to Compare the Bioavailability of Three Halobetasol Propionate 0.05% Topical Creams","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2004-01","conditions":"Healthy","enrollment":60},{"nctId":"NCT00802958","phase":"","title":"Randomized Study to Compare the Bioavailability of Two Halobetasol Propionate 0.05% Topical Ointments","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2003-07","conditions":"Healthy","enrollment":76},{"nctId":"NCT03298581","phase":"PHASE2","title":"Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2017-01-01","conditions":"Plaque Psoriasis","enrollment":""},{"nctId":"NCT04571151","phase":"PHASE4","title":"Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis","status":"UNKNOWN","sponsor":"Skin Sciences, PLLC","startDate":"2021-01","conditions":"Plaque Psoriasis","enrollment":30},{"nctId":"NCT02785185","phase":"PHASE2","title":"Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2016-06","conditions":"Psoriasis","enrollment":150},{"nctId":"NCT02045277","phase":"PHASE2","title":"Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2014-02","conditions":"Plaque Psoriasis","enrollment":212},{"nctId":"NCT02785172","phase":"PHASE2","title":"Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2016-04","conditions":"Psoriasis","enrollment":154},{"nctId":"NCT02515097","phase":"PHASE3","title":"Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-11-05","conditions":"Plaque Psoriasis","enrollment":213},{"nctId":"NCT02514577","phase":"PHASE3","title":"Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-11-07","conditions":"Plaque Psoriasis","enrollment":217},{"nctId":"NCT02462083","phase":"PHASE3","title":"Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-08-11","conditions":"Plaque Psoriasis","enrollment":555},{"nctId":"NCT03245385","phase":"PHASE2","title":"Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis","status":"TERMINATED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2017-07-24","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00990561","phase":"PHASE4","title":"Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-07","conditions":"Stable Plaque Psoriasis","enrollment":40},{"nctId":"NCT03058744","phase":"PHASE1","title":"Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-04","conditions":"Psoriasis","enrollment":94},{"nctId":"NCT01111123","phase":"PHASE4","title":"Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2009-01","conditions":"Plaque Psoriasis","enrollment":55},{"nctId":"NCT01166646","phase":"PHASE2","title":"Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2010-07","conditions":"Plaque Psoriasis","enrollment":43},{"nctId":"NCT01610596","phase":"PHASE2","title":"A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2011-11","conditions":"Psoriasis, Plaque Psoriasis","enrollment":72},{"nctId":"NCT01404338","phase":"PHASE1","title":"Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis","status":"COMPLETED","sponsor":"Patel, Rita Vikram, M.D.","startDate":"2011-06","conditions":"Psoriasis","enrollment":10},{"nctId":"NCT00715975","phase":"PHASE2, PHASE3","title":"Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2008-07","conditions":"Psoriasis","enrollment":140},{"nctId":"NCT00865267","phase":"PHASE1","title":"The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2003-12","conditions":"Healthy","enrollment":20},{"nctId":"NCT00865605","phase":"PHASE1","title":"Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2003-12","conditions":"Healthy","enrollment":71},{"nctId":"NCT00234728","phase":"NA","title":"Study of a New Dressing for Use With Topical Medications","status":"COMPLETED","sponsor":"Teikoku Pharma USA, Inc.","startDate":"2005-09","conditions":"Psoriasis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[{"count":307,"reaction":"DRUG INEFFECTIVE"},{"count":239,"reaction":"PSORIASIS"},{"count":130,"reaction":"RASH"},{"count":122,"reaction":"PRURITUS"},{"count":97,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":87,"reaction":"PAIN"},{"count":78,"reaction":"DIARRHOEA"},{"count":75,"reaction":"NAUSEA"},{"count":74,"reaction":"DERMATITIS ATOPIC"},{"count":72,"reaction":"ARTHRALGIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[{"date":"20070424","type":"ORIG","sponsor":"COSETTE","applicationNumber":"ANDA078162"},{"date":"20151106","type":"ORIG","sponsor":"LACER PHARMA","applicationNumber":"NDA208183"},{"date":"20200827","type":"SUPPL","sponsor":"LACER PHARMA","applicationNumber":"NDA208183"},{"date":"20201006","type":"ORIG","sponsor":"QUAGEN","applicationNumber":"ANDA213560"},{"date":"20230811","type":"ORIG","sponsor":"PADAGIS ISRAEL","applicationNumber":"ANDA215266"},{"date":"20050614","type":"ORIG","sponsor":"COSETTE","applicationNumber":"ANDA077109"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":125,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"halobetasol","genericName":"halobetasol","companyName":"Azidus Brasil","companyId":"azidus-brasil","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}